December 13, 2018 10:27 AM ESTUpdated 10:42 AM

Flagship-backed Foghorn woos Bristol-Myers vet Carl Decicco to direct its 'gene traffic control' platform

Amber Tong

A number of years ago, Carl Decicco happened to catch a presentation by a young Dana-Farber researcher named Cigall Kadoch. She was talking about the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Flagship-backed Foghorn woos Bristol-Myers vet Carl Decicco to direct its 'gene traffic control' platform

Amber Tong

Sign up to read this article for free.

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Flag­ship-backed Foghorn woos Bris­tol-My­ers vet Carl De­ci­c­co to di­rect its 'gene traf­fic con­trol' plat­form

Amber Tong

Sign up to read this article for free.

more like this

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Flagship-backed Foghorn woos Bristol-Myers vet Carl Decicco to direct its 'gene traffic control' platform

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial